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ABSTRACT 
Objective: The objective of the present study was to develop potent and non toxic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) by using 
heterocyclic nuclei and having Nitric Oxide releasing group.  
Methods: The compounds were designed with the help of docking studies. In the synthetic study, the target compounds were obtained by reacting 
substituted diphenyl imidazole benzoic acid (2a-2x) with nitro-oxy alkyl bromide in the presence of dimethyl formamide and potassium carbonate 
to give substituted 2,4-diphenyl nitric oxide releasing imidazole derivatives (3a-3x). The synthesized compounds were characterized with the help 
of different analytical studies and further evaluated for anti-inflammatory, analgesic and nitric oxide releasing activity. 
Results: In the docking study compounds 3a, 3b, 3c, 3e, 3r and 3s showed significant G-score. In the anti-inflammatory and analgesic study 
compounds 3a, 3b, 3c, 3e, 3r and 3s exhibited promising activity. All the synthesized compounds exhibited significant nitric oxide releasing 
properties both in-vitro and in-vivo.  
Conclusion: Compounds 3a, 3b, 3c, 3e, 3r and 3s exhibited prominent anti-inflammatory and analgesic activity.  
Keywords: Imidazole, Docking, Anti-inflammatory, Analgesic, Nitric oxide. 
 
INTRODUCTION 
Painkiller is the most commonly taken drug today, it reduces mainly 
the fever and inflammation. Selective Cyclo-oxygenase-2 (COX-2) 
inhibitors elicit less or no GI damage and bleeding compared with 
conventional Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), 
although the magnitude of this reduction continues to be debated in 
the literature [1]. As widely reported in the lay press, the selective 
COX-2 inhibitors also cause significant adverse effects in the renal 
and cardiovascular systems, possibly more serious than those 
caused by conventional NSAIDs.  
Recent strategies adopted to minimize the side effects of NSAIDs 
include the use of the dual LOX/COX inhibitors, the use of selective 
COX-2 inhibitors, and the use of hybrid molecules made up of non-
selective or selective COX inhibitors together with a nitric oxide-
releasing functional group [2-4]. 
The imidazole ring forms the core of many pharmacological important 
molecules having a wide array of activities like anti-inflammatory [5-
7], anticancer, antimicrobial and antioxidant [8]. The top selling active 
pharmaceutical ingredients comprise of an imidazole nucleus are 
losartan, olmesartan and ondasetron. The imidazole derivatives are 
also found naturally in the amino acid like histidine, in vitamin B12 
and a component of the DNA base structure.  
Synthetic approaches based on chemical modification of NSAIDs 
have been taken with the aim of improving safety profile and in turn 
therapeutic window of the resultant NSAIDs. Our previous studies 
had described the synthesis of hybrid molecules with nitric oxide-
releasing group that resulted in an increased anti-inflammatory 
activity with reduced GI-ulcerogenicity [1].  
In our attempt to continue to discover new, safer, and potent agents 
for the treatment of inflammatory diseases, we have synthesized 
compounds containing pharmacophore of 1,3,5 triaryl imidazole 
ring, the pharmacophore somewhat similar to coxibs and nitric 
oxide-releasing group to accentuate potency and reduce GI toxicities 
associated with the traditional NSAIDs. The compounds designed so 
were found to possess much significant anti-inflammatory, analgesic 
with significant nitric oxide releasing activity. 
MATERIALS AND METHODS 
Synthetic studies 
All the compounds were synthesized using the reported literature 
procedures, and synthetic procedures were set and optimized as and 
were required. All the chemicals & solvents were purchased from 
avra chemicals & sigma-aldrich. Melting points were uncorrected & 
recorded on optimelt digital melting point apparatus. IR spectra 
were recorded on bruker alpha E FTIR spectrophotometer.1HNMR 
were recorded on varian 400MHz spectrometer by using TMS as 
internal standard and CDCl3 as a solvent. Mass spectra were 
recorded on scinpor Q-TOF.  
General procedure for the synthesis of 2-bromo-1-(substituted 
phenyl)-ethanone(1a-1x) 
A solution of 0.42 moles of acetophenone in pure anhydrous ether 
was placed in two neck round bottom flask fitted with a reflux 
condenser. The solution was cooled in an ice bath and 0.5 g of 
anhydrous aluminum chloride was introduced and 0.42 moles of 
bromine were added gradually with stirring. After the addition of 
bromine, ether and the dissolved hydrogen bromide were removed 
under reduced pressure. The product was remained as a solid mass. 
The crude product was recrystallized from methanol. 
General procedure for the synthesis of 4-(2-(substituted phenyl)-
4-(substituted phenyl) imidazol-1-yl)-benzoic acid (2a-2x) 
A mixture of benzaldehyde (2 mmol), p-amino benzoic acid (2 
mmol), substituted bromophenylethanone (1a-1x, 2 mmol) and 
ammonium acetate (3 mmol) was stirred at 130 °C for 2 h, then the 
reaction mixture was cooled to room temperature and the product 
precipitated from a 1:1 mixture of acetone–water and then 
recrystallized from n-hexane–ethyl acetate [9]. 
Synthesis of nitrooxy ethyl bromide 
A bromo alcohol (10 mmol) was added drop wise to a solution of 
70% HNO3 (1.1 ml) and 95% H2SO4 (2.4 ml) at 0 °C, and the reaction 
was allowed to proceed at the same temperature for 1 h with 
stirring. The resulting suspension was poured into water (50 ml), 
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extracted with CH2Cl2 (3 × 200 ml), and dried MgSO4, and the solvent 
was removed to give the nitrooxy ethyl bromide [10]. 
General procedure for the synthesis of 2-(nitrooxy)-ethyl-4-(2-
(substitutedphenyl)-4-(substitutedphenyl)-1H-imidazol-1-yl)-
benzoate (3a-3x) 
A solution of 2-nitooxyethyl bromide (1.2 mmol), substituted 
diphenyl imidazole benzoic acid (2a-2x, 1 mmol) and K2CO3 (1.5 
mmol) in dry DMF (5 ml) was stirred at 25 °C for 12 h. Water (15 ml) 
was added, and the mixture was extracted with EtOAc (3 × 20 ml) 
and washed with brine (20 ml). The EtOAc fraction was dried over 
Na2SO4, the solvent was removed in vacuo, and the residue obtained 
was purified by silica gel column chromatography using ethyl 
acetate−hexane (1:1, v/v) as eluent to furnish compound [11]. 
Analytical data 
2-(nitrooxy)ethyl-4-(2,4-diphenyl-1H-imidazol-1-yl)benzoate (3a) 
White solid; IR: 3052, 2880, 1730, 1540, 1680, 1580 cm-1 1HNMR 
(400 MHz, CDCl3): δ= 4.6 (t, 2H,CH2), 4.7 (t,2H, CH2), 7.01 (m, 4H, 
CH), 7.22 (m, 3H, CH), 7.25 (d, 3H, CH), 7.40 (m, 2H, CH), 7.45 (d, 2H, 
CH), 8.40 (s,1H,CH). MS: m/z 430 [M+H]+. Elemental analysis: Found 
C (67.11), H (4.47), N(9.80) Calculated C (67.13), H (4.46), N (9.79).  
2-(nitrooxy)ethyl-4-(4-phenyl-2-(pyridin-2-yl)-1H-imidazol-1-
yl)benzoate (3b) 
Yellow solid; IR: 3070, 2851, 1745, 1555, 1590, 1627 cm-1  1HNMR 
(400 MHz, CDCl3):δ= 4.56 (t, 2H,CH2), 4.69 (t, 2H, CH2), 7.21 (m, 4H, 
CH), 7.30 (m, 3H, CH), 7.41 (d, 2H, CH), 7.5 (m, 2H, CH), 7.6 (d, 2H, CH), 
8.63 (s, 1H, CH). MS: m/z 431 [M+H]+. Elemental analysis: Found C 
(64.19), H (4.22), N (13.01) Calculated C (64.18), H (4.22), N (13.02). 
2-(nitrooxy)ethyl-4-(4-phenyl-2-(thiophen-2-yl)-1H-imidazol-
1-yl)benzoate (3c) 
Off white solid; IR: 3060, 2857, 1755, 1528, 1657, 1587 cm-1 1HNMR 
(400 MHz, CDCl3):δ= 4.18 (t, 2H,CH2), 4.35 (t, 2H, CH2), 7.22 (m, 4H, 
CH), 7.32 (m, 3H, CH), 7.45 (d, 3H, CH), 7.48 (m, 2H, CH), 8.6 (s, 1H, 
CH). MS: m/z 436 [M+H]+. Elemental analysis: Found C (60.69), H 
(3.94), N (9.67) Calculated C (60.68), H (3.93), N (9.65). 
2-(nitrooxy)ethyl-4-(2-(4-chlorophenyl)-4-phenyl-1H-imidazol-
1-yl)benzoate (3d) 
Buff solid; IR: 3090, 2940, 1695, 1535, 1680, 1535 cm-1 1HNMR (400 
MHz, CDCl3):δ= 4.48 (t, 2H,CH2), 4.66 (t, 2H, CH2), 7.18 (m, 4H, CH), 
7.31 (m, 3H, CH), 7.44 (d, 3H, CH), 7.52 (m, 3H, CH), 8.33 (s, 1H, CH). 
MS: m/z 464 [M+H]+. Elemental analysis: Found C (62.17), h (3.89), 
N (9.08) Calculated C (62.14), H (3.91) N (9.06). 
2-(nitrooxy)ethyl-4-(2-(4-fluorophenyl)-4-phenyl-1H-imidazol-
1-yl)benzoate (3e) 
White solid; IR: 3011, 2955, 1709, 1522, 1626, 1563 cm-1 1HNMR 
(400 MHz, CDCl3):δ= 4.42 (t, 2H,-CH2), 4.7 (t,2H,-CH2), 7.20 (m, 4H, 
CH), 7.30 (m, 3H, CH), 7.40 (d, 3H, CH), 7.55 (m, 3H, CH), 8.69 (s, 1H, 
CH). MS: m/z 448 [M+H]+. Elemental analysis: Found C (64.45), H 
(4.08), N (9.37) Calculated C (64.43), H (4.06), N (9.39). 
2-(nitrooxy)ethyl-4-(2-(4-cyanophenyl)-4-phenyl-1H-imidazol-
1-yl)benzoate (3f) 
Pale yellow solid; IR: 3034, 2848, 1696, 1535, 1598, 1636, 2242 cm-1 
1HNMR (400 MHz, CDCl3):δ= 4.5 (t, 2H,CH2), 4.68 (t, 2H, CH2), 7.22 
(m, 4H, CH), 7.32 (m, 3H, CH), 7.5 (d, 3H, CH), 7.52 (m, 3H, CH), 8.65 
(s, 1H, CH). MS: m/z 455 [M+H]+. Elemental analysis: Found C 
(66.09), H (4.01), N (12.34) Calculated C (66.08), H (3.99), N (12.33). 
2-(nitrooxy)ethyl-4-(2-(4-methoxyphenyl)-4-phenyl-1H-
imidazol-1-yl)benzoate (3g) 
White solid; IR: 3047, 2822, 1681, 1511, 1551, 1511, 1190 cm-1 
1HNMR (400 MHz, CDCl3):δ= 3.9 (s, 3H, CH3), 4.7 (t, 2H,CH2), 4.65 (t, 
2H, CH2), 7.11 (m, 4H, CH), 7.34 (m, 3H, CH), 7.44 (d, 3H, CH), 7.5 (m, 
3H, CH), 8.59 (s, 1H, CH). MS: m/z 460 [M+H]+. Elemental analysis: 




White solid; IR: 3044, 2888, 1787, 1565, 1520, 1627, 3370 cm-1 
1HNMR (400 MHz, CDCl3):δ= 4.5 (t, 2H,CH2), 4.6 (t,2H, CH2), 5.0 (s, 
1H, OH), 7.22 (m, 4H, CH), 7.30 (m, 3H, CH), 7.40 (d, 3H, CH), 7.55 
(m, 3H, CH), 8.46 (s, 1H, CH). MS: m/z 446 [M+H]+. Elemental 




Yellow solid; IR: 3087, 2817, 1781, 1533, 1532, 1172, 1607,3353 cm-
1 1HNMR (400 MHz, CDCl3):δ= 3.90 (s, 3H, CH3), 4.5 (t, 2H,CH2), 4.6 
(t,2H, CH2), 7.21 (m, 4H, CH), 7.35 (m, 3H, CH), 7.42 (d, 3H, CH), 7.55 
(m, 3H, CH), 8.62 (s, 1H, CH). MS: m/z 460 [M+H]+. Elemental 
analysis: Found C(65.36),H(4.63), N(9.17) Calculated C(65.35), 
H(4.61), N (9.15). 
2-(nitrooxy)ethyl-4-(4-(4-methoxyphenyl)-2-(pyridin-2-yl)-1H-
imidazol-1-yl)benzoate (3j) 
White solid; IR: 3096, 2829, 1795, 1555, 1518, 1148, 1632 cm-1 
1HNMR (400 MHz, CDCl3):δ= 3.92 (s, 3H, CH3), 4.44 (t, 2H,CH2), 4.5 (t, 
2H,CH2), 7.1 (m, 4H, CH), 7.35 (m, 3H, CH), 7.44 (d, 3H, CH), 7.52 (m, 
2H, CH), 8.61 (s, 1H, CH). MS: m/z 461 [M+H]+. Elemental analysis: 




Reddish brown solid; IR: 3105, 2810, 1787, 1540, 1530, 1157, 1642 
cm-1 1HNMR (400 MHz, CDCl3):δ= 3.85 (s, 3H, CH3), 4.56 (t, 2H,CH2), 
4.7 (t, 2H, CH2), 7.22 (t, 4H, CH), 7.35 (m, 3H, CH), 7.42 (d, 2H, CH), 
7.50 (m, 2H, CH), 8.64 (s, 1H, CH) MS: m/z 466 [M+H]+. Elemental 




White solid; IR: 3046, 2835, 1771, 1519, 1542, 1181, 1626 cm-1 
1HNMR (400 MHz, CDCl3):δ= 3.88 (s, 3H, CH3), 4.47 (t, 2H,CH2), 4.61 
(t, 2H, CH2), 7.22 (m, 4H, CH), 7.31 (m, 3H, CH), 7.43 (d, 3H, CH), 7.52 
(m, 2H, CH), 8.54 (s, 1H, CH). MS: m/z 494 [M+H]+. Elemental 
analysis: Found C(60.82),H(4.10), N(8.52) Calculated C(60.80), 
H(4.08), N (8.51). 
2-(nitrooxy)ethyl-4-(2-(4-fluorophenyl)-4-(4-methoxyphenyl)-
1H-imidazol-1-yl)benzoate (3m) 
White solid; IR: 3063, 2815, 1788, 1525, 1540, 1210, 1644 cm-1 
1HNMR (400 MHz, CDCl3):δ= 3.84 (s, 3H, CH3), 4.48 (t, 2H,CH2), 4.66 
(t, 2H, CH2), 7.18 (m, 4H, CH), 7.28 (m, 3H, CH), 7.3 (d, 3H, CH), 7.54 
(m, 2H, CH), 8.62 (s, 1H, CH). MS: m/z 478 [M+H]+. Elemental 




Pale yellow solid; IR: 3014, 2818, 1748, 1535, 1549, 1201, 2222, 
1595 cm-1 1HNMR (400 MHz, CDCl3):δ= 3.80 (s, 3H, CH3), 4.45 (t, 
2H,CH2), 4.65 (t, 2H, CH2), 7.22 (m, 4H, CH), 7.28 (m, 3H, CH), 7.35 (d, 
3H, CH), 7.4 (m, 2H, CH), 8.58 (s, 1H, CH). MS: m/z 485 [M+H]+. 
Elemental analysis: Found C (64.47), H (4.14), N (11.55) Calculated C 
(64.46), H (4.16), N (11.56). 
2-(nitrooxy)ethyl-4-(2,4-bis(4-methoxyphenyl)-1H-imidazol-1-
yl)benzoate (3o) 
White solid; IR: 3015, 2799, 1771, 1509, 1556, 1223, 1660 cm-1 
1HNMR (400 MHz, CDCl3):δ= 3.8 (m, 6H, CH3), 4.45 (t, 2H,CH2), 4.6 (t, 
2H, CH2), 7.20 (m, 4H, CH), 7.32 (m, 3H, CH), 7.40 (d, 3H, CH), 7.54 
(m, 2H, CH), 8.2 (s, 1H, CH). MS: m/z 490 [M+H]+. Elemental analysis: 
Found C(63.82), H(4.75), N(8.60) Calculated C(63.80), H(4.74), 
N(8.58). 
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2-(nitrooxy)ethyl-4-(2-(4-hydroxyphenyl)-4-(4-
methoxyphenyl)-1H-imidazol-1-yl) benzoate (3p) 
White solid; IR: 3080, 2829, 1742, 1511, 1549, 1199, 1660, 3369 cm-
1 1HNMR (400 MHz, CDCl3):δ= 3.82 (s, 3H, CH3), 4.45 (t, 2H,CH2), 4.6 
(t, 2H, CH2), 5.2 (s, 1H, OH), 7.20 (m, 4H, CH), 7.36 (m, 3H, CH), 7.44 
(d, 3H, CH), 7.52 (m, 2H, CH), 8.29 (s, 1H, CH). MS: m/z 476 [M+H]+. 
Elemental analysis: Found C (63.16), H (4.46), N (8.85) Calculated C 
(63.15), H (4.45), N(8.84). 
2-(nitrooxy)ethyl-4-(4-(4-fluorophenyl)-2-phenyl-1H-imidazol-
1-yl)benzoate (3q) 
Off white solid; IR: 3052, 2839, 1733, 1526, 1556, 1642 cm-1 1HNMR 
(400 MHz, CDCl3):δ= 4.5 (t, 2H,CH2), 4.7 (t, 2H, CH2), 7.22 (m, 4H, 
CH), 7.30 (m, 3H, CH), 7.4 (d, 3H, CH), 7.55 (m, 3H, CH), 8.7 (s, 1H, 
CH). MS: m/z 448 [M+H]+. Elemental analysis: Found C (64.44), H 
(4.05), N (9.37) Calculated C (64.43), H (4.06), N (9.39). 
2-(nitrooxy)ethyl-4-(4-(4-fluorophenyl)-2-(pyridin-2-yl)-1H-
imidazol-1-yl)benzoate (3r) 
White solid; IR: 3040, 2841, 1720, 1536, 1550, 1633 cm-1 1HNMR 
(400 MHz, CDCl3): δ 4.6 (t, 2H,CH2), 4.7 (t, 2H, CH2), 7.2 (m, 4H, CH), 
7.3 (m, 3H, CH), 7.43 (d, 3H, CH), 7.5 (m, 2H, CH), 8.0 (s, 1H, CH). MS: 
m/z 449 [M+H]+. Elemental analysis: Found C (61.62), H (3.84), N 
(12.50) Calculated C (61.61), H (3.82), N (12.49). 
2-(nitrooxy)ethyl-4-(4-(4-fluorophenyl)-2-(thiophen-2-yl)-1H-
imidazol-1-yl)benzoate (3s)  
White solid; IR: 3031, 2819, 1754, 1539, 1563, 1626 cm-1 1HNMR 
(400 MHz, CDCl3):δ= 4.5 (t, 2H,CH2), 4.7 (t, 2H, CH2), 7.25 (m, 4H, 
CH), 7.31 (m, 3H, CH), 7.45 (d, 3H, CH), 7.8 (m, 1H, CH), 8.0 (s, 1H, 
CH). MS: m/z 454 [M+H]+. Elemental analysis: Found C (58.28) H 
(3.57), N (9.29) Calculated C (58.27), H (3.56), N (9.27). 
2-(nitrooxy)ethyl-4-(2-(4-chlorophenyl)-4-(4-fluorophenyl)-
1H-imidazol-1-yl)benzoate (3t) 
Yellow solid; IR: 3081, 2840, 1752, 1513, 1540, 1612 cm-1 1HNMR 
(400 MHz, CDCl3): δ= 4.8 (t, 2H,CH2), 4.9 (t, 2H, CH2), 7.21 (m, 4H, 
CH), 7.30 (m, 3H, CH), 7.5 (d, 3H, CH), 7.55 (m, 2H, CH), 8.1 (s, 1H, 
CH). MS: m/z 482 [M+H]+. Elemental analysis: Found C (59.84), H 
(3.55), N (8.70) Calculated C (59.82), H (3.56), N (8.72). 
2-(nitrooxy)ethyl-4-(2,4-bis(4-fluorophenyl)-1H-imidazol-1-
yl)benzoate (3u) 
White solid; IR: 3045, 2856, 1740, 1548, 1565, 1629 cm-1 1HNMR 
(400 MHz, CDCl3):δ= 4.7 (t, 2H,CH2), 4.8 (t, 2H, CH2), 7.24 (m, 4H, 
CH), 7.38 (m, 3H, CH), 7.46 (d, 3H, CH), 7.54 (m, 2H, CH), 8.5 (s, 1H, 
CH). MS: m/z 466 [M+H]+. Elemental analysis: Found C (61.95), H 
(3.70), N (9.05) Calculated C (61.94), H (3.68), N (9.03). 
2-(nitrooxy)ethyl-4-(2-(4-cyanophenyl)-4-(4-fluorophenyl)-1H-
imidazol-1-yl)benzoate (3v) 
Off white solid; IR: 3080, 2822, 1710, 1517, 1535, 2210, 1626 cm-1 
1HNMR (400 MHz, CDCl3):δ= 4.52 (t, 2H,CH2), 4.64 (t, 2H, CH2), 7.24 (m, 
4H,-CH), 7.3 (m, 3H,-CH), 7.5 (d, 3H, CH), 7.55 (m, 2H, CH), 8.39 (s, 1H, 
CH). MS: m/z 473 [M+H]+. Elemental analysis: Found C (63.57), H (3.64), 
N (11.86), Calculated C (63.56), H (3.63), N (11.86). 
2-(nitrooxy)ethyl-4-(4-(4-fluorophenyl)-2-(4-methoxyphenyl)-
1H-imidazol-1-yl)benzoate (3w) 
White solid; IR: 3022, 2839, 1725, 1529, 1549, 2231, 1175, 1660 cm-
1 1HNMR (400 MHz, CDCl3):δ= 3.8 (s, 3H,-CH3), 4.52 (t, 2H,-CH2), 4.6 
(t, 2H,-CH2), 7.28 (m, 4H,-CH), 7.32 (m, 3H,-CH), 7.51 (d, 3H, CH), 7.6 
(m, 2H, CH), 8.19 (s, 1H, CH). MS: m/z 478 [M+H]+. Elemental 




Buff solid; IR: 2989, 2830, 1719, 1510, 1556, 2230, 3310, 1636 cm-1 
1HNMR (400 MHz, CDCl3):δ= 4.55 (t, 2H,-CH2), 4.6 (t, 2H,-CH2), 5.2 (s, 
1H,-OH), 7.22 (m, 4H,-CH), 7.30 (m, 3H,-CH), 7.52 (d, 3H, CH), 7.65 
(m, 2H, CH), 8.1 (s, 1H, CH). MS: m/z 464 [M+H]+. Elemental analysis: 




Swiss albino mice of either sex weighing 20–25 g and wistar rats 
weighing in the range 140–160 g were used. All the animals were 
housed under standard ambient conditions of temperature (25±2 
°C) and relative humidity of 50±5%. A 12/12-h light/dark cycle was 
maintained. All the animals were allowed to have free access to 
water and standard palletized laboratory animal diet 24 h before 
pharmacological studies. All the experimental procedures and 
protocols used in this study were reviewed and approved by the 
Institutional Animal Ethical Committee (IAEC) of the Department of 
Chemical Technology, Dr. Babasaheb Ambedkar Marathwada 
University, Aurangabad constituted in accordance with the 
guidelines of the Committee for the Purpose of Control and 
Supervision of Experiments on Animals, Government of India. 
Preparation of test compounds 
After suspending the test compounds in 1.0% aqueous solution of 
sodium carboxy methyl cellulose (CMC), the test samples were 
administered to the test animals orally. The positive and negative 
control group animals received the same experimental handling as 
those of the test groups except that the drug-treated control group 
animals received only appropriate volumes of the vehicle and of the 
reference drug, celecoxib. 
Anti-inflammatory activity 
Anti-inflammatory activity was evaluated using the well known 
carrageenan-induced rat paw edema model [12], using twenty six 
groups of six animals each. A freshly prepared aqueous suspension 
of carrageenan (1.0% w/v, 0.1 ml) was injected in the sub planter 
region of the right hind paw of each rat. One group was kept as 
control, and the animals of the other group were pre-treated with 
the test compounds, 1 h before the carrageenan treatment. The 
volume was measured before and after carrageenan treatment at 60 
min intervals with the help of digital plethysmometer. 
Analgesic activity 
The analgesic activity was evaluated using the acetic acid induced 
writhing method [13], using groups of six animals each. A solution of 
acetic acid (1% v/v) in distilled water was prepared and injected 
intraperitoneally in a volume of 0.1 ml. One group was kept as 
control, and the animals of the other group were pre-treated with 
the test compounds, 1 h before the acetic acid (1% v/v) treatment. 
The writhing episodes were recorded for 15 min, stretching 
movements consisting of arching of the back, elongation of the body, 
and extension of hind limbs was counted. 
In vitro and in vivo screening of nitric oxide 
Vasorelaxing activity [14] 
In order to determine a possible vasodilator mechanism of action, 
the compounds were tested on isolated aortae of male normotensive 
wistar rats (250–350 g). The rats were sacrificed by cervical 
dislocation under light ether anesthesia and bled. The aortae was 
immediately excised, freed of extraneous tissues and prepared as 
multiple-ring preparations. Then the vessels were suspended, under 
a preload of 2g in 10 ml organ baths, containing tyrode solution 
(composition of saline in mM: NaCl 136.8; KCl 2.95; CaCl2 1.80; 
MgSO4 7; H2O 1.05; NaH2PO4 0.41; NaHCO3 11.9; Glucose 5.5), 
thermostated at 37 °C and continuously bubbled with a mixture of 
O2 (95%) and CO2(5%). Changes in tension were recorded by means 
of an isometric transducer (BIOPAC System, Inc., MP 35, USA). After 
an equilibration period of 60 min, the endothelial integrity was 
confirmed by acetylcholine (ACh) (55 µM)-induced relaxation of 
norepinephrine (NE 20 µg/ml) pre contracted tissues. A relaxation ≥ 
70% of the NE induced contraction was considered representative of 
an acceptable presence of the endothelial layer, while the organs, 
showing a relaxation<70%, were not used in the experimental 
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procedures. At 30–40 min after the confirmation of the endothelial 
integrity, the aortic preparations were contracted by treatment with 
a single concentration of NE (20 µg/ml) or KCl (30 mM), and when 
the contraction reached a stable plateau, the test compounds in 
concentration (0.1 mg/ml) were added cumulatively. 
Detection of nitrite [15] 
A solution of the appropriate compound (20 µl) in dimethyl 
sulfoxide was added to 2 ml of 1:1 v/v mixture either of 50 mM 
phosphate buffer (pH 7.4) or of HCl solution (pH 1) with methanol, 
containing 5 × 10-4M L-cysteine. The final concentration of the test 
compound was 10-4 M. After 1 h at 37 °C, 1 ml of the reaction 
mixture was treated with 250 µl of Griess reagent [sulphanilamide 
(4 g), N-naphthyl ethylene diamine dihydrochloride (0.2 g), and 85% 
phosphoric acid (10 ml) in distilled water (final volume: 100 ml)]. 
After 10 min at room temperature, the absorbance was measured at 
540 nm. Sodium nitrite standard solutions (10–80 µmol/ml) were 
used to construct the calibration curve. The results were expressed 
as the percentage of NO released (n-2) relative to a theoretical 
maximum release of 1 mol NO/mol of test compound. 
Statistical analysis 
The data obtained for each set of anti-inflammatory model were 
expressed as the mean of change in paw volume±SD and analyzed by 
one-way ANOVA followed by Dunnett’s test. Data from acetic acid-
induced writhing model were expressed as the mean of the number 
of writhes±SEM and analyzed by one way ANOVA followed by 
Dunnett’s ‘t’ test. Level of significance was set to P<0.05. All the 
statistical calculations were performed using the evaluation version 
of Graph Pad Prism 3.0 (USA) statistical software. 
Docking methodology 
Molecular docking studies were performed using Glide v6.2 
(Schrödinger, LLC). The coordinates for COX-2 enzyme were taken 
from RCSB Protein Data Bank (PDB Id 1CX2) and prepared for 
docking using protein preparation wizard. Water molecules in the 
structure were removed and termini were capped by adding ACE 
and NMA residue.  
The bond orders and formal charges were added for hetero groups 
and hydrogens were added to all atoms in the structure. Side chains 
that were not close to the binding cavity and do not participate in 
salt bridges were neutralized. After preparation, the structures were 
refined to optimize the hydrogen bond network using OPLS_2005 
force field. This helps in reorientation of the side chain hydroxyl 
group. The minimization was terminated when the energy 
converged or the RMSD reached a maximum cut off of 0.30 Å. Grids 
were then defined around refined structure by centering on ligand 
using default box size. The extra precision (XP) docking mode for 
compounds, optimized by Ligprep, was performed on the generated 
grid of protein structure [16]. 
RESULTS AND DISCUSSION 
Chemistry 
The synthesis of target compounds 3a-3x is shown in scheme 1-2. 
Substituted acetophenones were brominated in the presence of 
aluminium chloride and ether to afford substituted bromo phenyl 
ethanone (1a-1x). The substituted bromo phenyl ethanone were 
further reacted with 4-amino benzoic acid, substituted 
benzaldehyde and ammonium acetate to give substituted diphenyl 
imidazole benzoic acid (2a-2x). Nitro-oxy ethyl bromide was 
prepared from bromoethanol in the presence of nitric acid and 
sulfuric acid (scheme 1). The target compounds were obtained by 
reacting substituted diphenyl imidazole benzoic acid (2a-2x) with 
nitro-oxy alkyl bromide in the presence of dimethyl formamide and 
potassium carbonate to give substituted 2,4-diphenyl nitric oxide 
releasing imidazole derivatives (3a-3x, scheme 2, table1). The 
structures of various synthesized compounds were assigned on the 
basis of results of different chromatographic and spectral studies. 
The physical data, FTIR, 1H-NMR, mass spectral data and elemental 
analysis data for all the synthesized compounds are given in 
experimental protocols. 
 
Scheme 1: Synthesis of intermediate nitro-oxy ethyl bromide. 
Reagents and conditions (a) 70% HNO3, 95% H2SO4, 0 °C, 1h
 
 
Scheme 2: Synthesis of compounds 3a-3x. Reagents and conditions (a) AlCl3, Et2O (b) 4-amino benzoic acid, substituted aldehydes, 
NH4OAc, solvent free, 120 °C, 2h (c) O2NO-CH2-CH2-Br, DMF, K2CO3, 25 °C, 12 h 
 
Pharmacology 
The synthesized compounds were subjected to the evaluation of 
anti-inflammatory activity, analgesic activity and nitric oxide-
releasing properties. Celecoxib was used as reference standard. The 
experiments were performed using albino rats of wistar strain of 
either sex, weighing in the range of 140–160 g. The animals were 
maintained at 25±2 °C, 50±5% relative humidity and 12-h light/dark 
cycle. All the animals were fasted for 24 h before the experiments 
and water was provided ad libitum. The test compounds were 
suspended in 1% aqueous carboxy methyl cellulose (CMC) solution 
and administered orally to experimental animals for all the studies. 
Anti-inflammatory activity 
Anti-inflammatory activity of the synthesized compounds was 
evaluated by carrageenan-induced rat paw edema model and 
equimolar doses are equivalent to celecoxib. Sub-planter injection of 
0.1 ml of 1% carrageenan in rat paw increased the paw volume 
(edema) in all the animals of various groups. The onset of action was 
evident during1 h in various test groups. The significant (P<0.01) 
reduction of rat paw edema was observed for most of the test 
compounds, at 3 h compared to control group and celecoxib (table 2).  
Out of the synthesized compounds 3a, 3b, 3c, 3e, 3r and 3s (68.13–
72.54%) exhibited very significant anti-inflammatory activity 
compared to standard drug celecoxib (71.56% at 3 h).  
Thus, the compounds having a substitution of hydrogen on R1 
position and phenyl, pyridine, thiophene and fluoro group on the 
phenyl ring respectively at R2 position (3a, 3b, 3c, 3e) show 
equipotent activity with celecoxib. Compound 3r and 3s also shows 
equipotent activity in which R1 position is occupied by the fluoro 
group and R2 position is occupied with pyridine and thiophene ring. 
Compound 3k and 3u shows decreased anti-inflammatory activity. 
(In compound 3k, R1 position is occupied by methoxy group and R2 
position is occupied by the thiophene ring, whereas in compound 3u, 
R1 and R2 both positions are occupied by fluoro group). Based on the 
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findings of these preclinical results, further studies need to be 
carried out to investigate the other specifications, such as in vitro 
assays, toxicological studies and the mechanism by which these 
drugs exhibit potential analgesic, anti-inflammatory activities.
 
Table 1: Characterization data for synthesized compounds (3a-3x) 
S. No. Entry R1 R2 MF MW % yield MP( °C) 
1 3a -H C6H5 C24H19N3O5 429 88 145-146 
2 3b -H 
 
C23H18N4O5 430 69 174-176 
3 3c -H 
 
C22H17N3O5S 435 72 136-137 
4 3d -H 4-ClC6H4 C24H18ClN3O5 463 85 155-157 
5 3e -H 4-FC6H4 C24H18FN3O5 447 88 165-166 
6 3f -H 4-CNC6H4 C25H18N4O5 454 80 188-189 
7 3g -H 4-MeOC6H4 C25H21N3O6 459 74 122-123 
8 3h -H 4-OHC6H4 C24H19N3O6 445 86 203-204 
9 3i 4-MeO C6H5 C25H21N3O6 459 80 222-223 
10 3j 4-MeO 
 
C24H20N4O6 460 70 214-215 
11 3k 4-MeO 
 
C23H19N3O6S 465 68 189-190 
12 3l 4-MeO 4-ClC6H4 C25H20ClN3O6 493 82 236-237 
13 3m 4-MeO 4-FC6H4 C25H20FN3O6 477 64 206-207 
14 3n 4-MeO 4-CNC6H4 C26H20N4O6 484 60 109-111 
15 3o 4-MeO 4-MeOC6H4 C26H23N3O7 489 79 129-130 
16 3p 4-MeO 4-OHC6H4 C25H21N3O7 475 83 228-229 
17 3q 4-F C6H5 C24H18FN3O5 447 86 220-221 
18 3r 4-F 
 
C23H17FN4O5 448 67 170-172 
19 3s 4-F 
 
C22H16FN3O5S 453 63 196-197 
20 3t 4-F 4-ClC6H4 C24H17ClFN3O5 481 87 175-176 
21 3u 4-F 4-FC6H4 C24H17F2N3O5 465 89 150-151 
22 3v 4-F 4-CNC6H4 C25H17FN4O5 472 82 133-134 
23 3w 4-F 4-MeOC6H4 C25H20FN3O6 477 81 178-179 
24 3x 4-F 4-OHC6H4 C24H18FN3O6 463 85 139-140 
 
Table 2: Results of anti-inflammatory activity of synthesized compounds (3a-3x) against carrageenan-induced rat paw edema model in rats 
Compound Code Change in paw volume in (ml) after drug treatment(±SEM) Anti-inflammatory activity (% Inhibition) 
 1h 2h 3h 1h 2h 3h 
Control 1.72±0.038** 1.93±0.05** 2.04±0.017** - - - 
Celecoxib 0.67±0.019** 0.63±0.024** 0.58±0.07** 61.04 67.35 71.56 
3a 0.69±0.055** 0.67±0.063** 0.63±0.085** 59.88 65.28 69.11 
3b 0.65±0.07** 0.62±0.041** 0.56±0.012** 62.20 67.87 72.54 
3c 0.66±0.065** 0.64±0.028** 0.58±0.022** 61.62 66.83 71.07 
3d 1.11±0.035** 1.13±0.09** 1.16±0.020** 35.46 41.45 43.13 
3e 0.72±0.049** 0.68±0.062** 0.65±0.051** 58.13 64.76 68.13 
3f 0.79±0.040** 0.76±0.04** 0.74±0.079** 54.06 60.62 63.72 
3g 0.93±0.021** 0.91±0.022** 0.88±0.047** 45.93 52.84 56.86 
3h 1.01±0.044** 1.06±0.050** 1.09±0.009** 39.53 45.07 46.56 
3i 0.83±0.019** 0.81±0.011** 0.78±0.049** 51.74 58.03 61.76 
3j 1.03±0.033** 1.06±0.032** 1.08±0.039** 40.11 45.07 47.05 
3k 1.13±0.06** 1.15±0.033** 1.17±0.026** 34.30 40.41 42.64 
3l 0.71±0.011** 0.68±0.027** 0.66±0.004** 58.72 64.76 67.64 
3m 1.01±0.043** 1.05±0.08** 1.07±0.052** 41.27 45.59 47.54 
3n 0.73±0.063** 0.71±0.052** 0.68±0.027** 57.55 63.21 66.66 
3o 0.90±0.038** 0.88±0.005** 0.85±0.042** 47.67 54.40 58.33 
3p 1.06±0.019** 1.08±0.039** 1.11±0.008** 38.37 44.04 45.58 
3q 0.91±0.009** 0.88±0.047** 0.86±0.062** 47.09 54.40 57.84 
3r 0.68±0.069** 0.66±0.090** 0.64±0.063** 60.46 65.80 68.62 
3s 0.66±0.044** 0.63±0.046** 0.60±0.066** 61.62 67.35 70.58 
3t 0.88±0.041** 0.84±0.03** 0.81±0.036** 48.83 56.47 60.29 
3u 1.12±0.008** 1.15±0.070** 1.17±0.072** 34.88 40.41 42.64 
3v 0.81±0.035** 0.79±0.039** 0.76±0.009** 52.90 59.06 62.74 
3w 0.99±0.077** 0.97±0.051** 0.94±0.059** 42.44 49.74 53.92 
3x 1.03±0.080** 1.05±0.026** 1.08±0.044** 40.11 45.59 47.05 
Data analyzed by one way ANOVA followed by Dunnett’s ‘t’ test, (n = 6), * P<0.05, ** P<0.01 significant from control ns not significant 
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Analgesic activity 
The analgesic activity of the synthesized compounds was studied by 
using acetic acid-induced writhing test in mice. The analgesic 
activity was evaluated at equimolar doses equivalent to celecoxib. 
The important analgesic profile of the compounds was measured by 
the classical acetic acid-induced writhing model. From the results, it 
was noticed that all the compounds possess significant analgesic 
activity (table 3). The analgesic effect of compounds 3a, 3b, 3c, 3e, 3r 
and 3s (61.68-66.11%) were found to be equipotent compared to 
standard drug celecoxib (66.56%) similar to anti-inflammatory 
activity. Compound 3d and 3h shows decreased analgesic activity 
due to substitution of hydrogen at R1 position and chloro, hydroxyl 
group on the phenyl ring respectively at R2 position. 
 
Table 3: Results of analgesic activity of synthesized compounds (3a-3x) against acetic acid-induced writhing test in mice 
Compound Code No of Writhes in 5-15 min. after treatment (mean±SE) % Inhibition 
Control 26.41±0.57** - 
Celecoxib 8.83±0.19** 66.56 
3a 9.21±0.28** 65.12 
3b 9.85±0.11** 62.70 
3c 8.95±0.13** 66.11 
3d 14.36±0.11** 45.62 
3e 10.12±0.67** 61.68 
3f 13.42±0.38** 49.18 
3g 12.35±0.17** 53.23 
3h 14.21±0.90** 46.19 
3i 10.91±0.82** 58.68 
3j 13.98±0.62** 47.06 
3k 14.09±0.49** 46.64 
3l 12.86±0.44** 51.30 
3m 13.03±0.09** 50.60 
3n 11.36±0.30** 56.98 
3o 12.69±0.35** 61.64 
3p 11.94±0.78** 54.78 
3q 12.17±0.77** 53.91 
3r 9.67±0.33** 63.38 
3s 9.03±0.46** 65.80 
3t 10.55±0.29** 60.05 
3u 13.24±0.29** 49.98 
3v 11.99±0.66** 54.60 
3w 12.65±0.94** 52.10 
3x 13.59±0.39** 48.54 
Data analyzed by one way ANOVA followed by Dunnett’s ‘t’ test,(n = 6), ** P<0.01 significant from control 
 
Table 4: EC50 values and nitric oxide-releasing properties of the compounds (3a–3x) 
S. No. Compound Code EC50 % NO release 
1 3a 39.85 0.46 
2 3b 48.54 0.32 
3 3c 37.75 0.49 
4 3d 45.55 0.59 
5 3e 31.16 0.65 
6 3f 50.41 0.78 
7 3g 28.56 0.30 
8 3h 33.45 0.33 
9 3i 55.30 0.44 
10 3j 29.65 0.70 
11 3k 32.07 0.55 
12 3l 36.22 0.61 
13 3m 52.06 0.49 
14 3n 49.12 0.52 
15 3o 42.22 0.77 
16 3p 33.10 0.37 
17 3q 36.85 0.68 
18 3r 46.93 0.66 
19 3s 44.68 0.34 
20 3t 35.20 0.62 
21 3u 34.87 0.55 
22 3v 37.73 0.51 
23 3w 39.65 0.58 
24 3x 46.22 0.43 
 
Nitric oxide-release study 
In isolated wistar rat aorta rings, compounds 3a-3x competitively 
inhibited norepinephrine-induced contraction effects, causing a shift 
to the right of the norepinephrine concentration response curves. 
EC50 (µg/ml) values were calculated from the cumulative 
concentration response curves. In order to prove the involvement of 
nitric oxide in the relaxation process, nitric oxide-releasing 
properties of synthesized compounds were assessed in phosphate 
buffer, pH 7.4, in the presence of L-cysteine, relative to nitric oxide 
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released from standard sodium nitrite solution (table 4). From in 
vitro nitric oxide releasing data, it is observed that compound 3f and 
3o shows potent nitric oxide releasing properties, whereas 
compound 3b and 3h shows less nitric oxide releasing properties. 
From nitric oxide releasing activity of rat aortic muscle, it is 
observed that compound 3g and 3j shows potent EC50 values, 
whereas compound 3i and 3m shows less EC50 value. 
Docking study 
In all series, the docking poses of compounds showing higher 
docking score (G-score) were compared with that of standard 
celecoxib in the active site of the COX-2 enzyme. Similarly the 
docking pose of all other compounds were compared with that of 
compound showing higher G-score within the series for comparing 
their pharmacophoric features desired for good binding affinity 
toward COX-2 enzyme. 
The docking study of imidazole derivatives showed that only some 
of all compounds were docked and few of them showed comparable 
binding affinity toward COX-2 enzyme (table 5). This may be due to 
triaryl ring system of imidazole derivatives compared to diaryl rings 
in celecoxib (fig. 1). The compound 3b showed the good G-score and 
thus higher binding affinity for the COX-2 enzyme among the 
imidazole derivatives.  
The pyridine ring in compound 3b at R2 position formed the hydrogen 
bond with amino acid Tyr 355 which further supports the ligand-
enzyme complex (fig. 2). Thus the replacement of pyridine at R2 position 
by substituted phenyl ring in other compounds, exhibited the decreased 
binding affinity of compounds toward COX-2 enzyme, due to lack of H-
bond with surrounding amino acids by substituents at R2 position (fig. 3). 
However, the compounds substituted by unsubstituted phenyl ring and 
thiophene ring showed comparably good binding affinity than the 
compounds containing substituted phenyl ring at R2 position.  
 
Table 5: Docking score of compounds (3a-3x) 
S. No. Entry G Score H Bond Lipophilic EvdW Phob En 
1 Celecoxib -10.5 -1.3 -6.1 -1.5 
2 3a -7.32 0 -2.29 -4.86 
3 3b -7.91 -0.66 -2.23 -4.36 
4 3c -7.67 -0.99 -1.87 -4.29 
5 3d -4.25 0 -2.26 -5.27 
6 3e -6.69 0 -2.11 -4.04 
7 3f -4.52 0 -2.61 -4.9 
8 3g ND* ND* ND* ND* 
9 3h ND* ND* ND* ND* 
10 3i ND* ND* ND* ND* 
11 3j ND* ND* ND* ND* 
12 3k -2.1 0 0 -2.8 
13 3l ND* ND* ND* ND* 
14 3m ND* ND* ND* ND* 
15 3n ND* ND* ND* ND* 
16 3o ND* ND* ND* ND* 
17 3p ND* ND* ND* ND* 
18 3q ND* ND* ND* ND* 
19 3r -7.8 -0.66 -2.47 -4.1 
20 3s -6.37 0 -2.25 -3.74 
21 3t ND* ND* ND* ND* 
22 3u -0.78 0 0 -2.11 
23 3v ND* ND* ND* ND* 
24 3w ND* ND* ND* ND* 
25 3x ND* ND* ND* ND* 
ND* Not Docked, H Bond: Chem score hydrogen bond pair term, Lipophilic EvdW: Chem score lipophilic pair term and fraction of total protein 




Fig. 1: Docking pose of celecoxib in active site of COX-2 enzyme 
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Fig. 2: Docking pose of compound 3b in active site of COX-2 enzyme 
 
 
Fig. 3: Docking pose of compound 3f in active site of COX-2 enzyme 
 
 
Fig. 4: Docking pose of compound 3a in active site of COX-2 enzyme 
 
Similarly, un substitution and substitution by fluorine atom at 
R1 position help the compounds 3a-3c and 3r-3s to fit properly 
in the surrounding hydrophobic pocket of the COX-2 enzyme 
(fig. 4).  
Thus the replacement of hydrophobic substituents by an electron 
withdrawing group (OCH3) at R1 position decreases the hydrophobic 
interaction with surrounding amino acids and thus the binding 
affinity of compounds (fig. 5). 
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Fig. 5: Docking pose of compound 3k in active site of COX-2 enzyme 
 
CONCLUSION 
Twenty four compounds were synthesized and screened for 
analgesic, anti-inflammatory and nitric oxide-releasing studies. 
Docking study of these synthesized compounds was also performed. 
Most of the compounds exhibited significant anti-inflammatory, 
analgesic and nitric oxide releasing activity. Compounds 3a, 3b, 3c, 
3e, 3r and 3s exhibited more prominent and constitute anti-
inflammatory activity. Compounds 3a, 3b, 3c, 3e, 3r and 3s showed 
strong analgesic activity in the acetic acid-induced writhing tests. 
From the detailed analysis of the results of pharmacological studies, 
we conclude that the synthesized compounds have not only retained 
but showed enhanced anti-inflammatory profile. Also, all the 
synthesized derivatives exhibited significant vasorelaxant activity 
that is devoid of CVS toxicities associated with coxib families of COX-
2 inhibitors. Therefore, it can be concluded that the rational, based 
on which these NCEs were designed, has been proven to be superior 
compared to the currently used NSAIDs. The outcome of this 
research study is very promising. The only concern to be addressed 
now is the pharmacokinetics profile of the designed NCEs, since 
molecular weight of all the designed compounds is beyond 500. The 
most potent derivatives are in the process for chronic toxicity and 
pharmacokinetic studies, based on those results, a further action 
plan will be finalized. 
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